The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023

Wang, Feng‐Hua; Zhang, Xiao‐Tian; Tang, Lei; Wu, Qi; Cai, Mu‐Yan; Li, Yuan‐Fang; Qu, Xiu‐Juan; Qiu, Hong; Zhang, Yu‐Jing; Ying, Jie‐Er; Zhang, Jun; Sun, Ling‐Yu; Lin, Rong‐Bo; Wang, Chang; Liu, Hao; Qiu, Miao‐Zhen; Guan, Wen‐Long; Rao, Sheng‐Xiang; Ji, Jia‐Fu; Xin, Yan; Sheng, Wei‐Qi; Xu, Hui‐Mian; Zhou, Zhi‐Wei; Zhou, Ai‐Ping; Jin, Jing; Yuan, Xiang‐Lin; Bi, Feng; Liu, Tian‐Shu; Liang, Han; Zhang, Yan‐Qiao; Li, Guo‐Xin; Liang, Jun; Liu, Bao‐Rui; Shen, Lin; Li, Jin; Xu, Rui‐Hua

doi:10.1002/cac2.12516

Cited by 20 publications

(7 citation statements)

References 363 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Cox model was used in some studies to show that the risk of death in stage III patients is 2.82 times that in stage II patients, and that in stage IV patients is 3.29 times that in stage II patients [ 21 ]. The presence of PTNM serves as a significant independent prognostic indicator for patients with gastric cancer patients [ 25 , 26 ] and can forecast patients’ prognosis and offer treatment recommendations. The prognosis of patients varied significantly across different disease stages.…”

Section: Discussionmentioning

confidence: 99%

Analysis of multiple factors influencing the survival of patients with advanced gastric cancer

Zhu,

Ge,

Wen

et al. 2024

Aging

View full text Add to dashboard Cite

Objective: The aim of this study was to investigate the main factors influencing the survival of patients with advanced gastric cancer. Methods: The clinicopathological data of 120 patients with advanced gastric cancer were analyzed retrospectively, and clinical and pathological data were collected. Tumor tissue staging and grading were reevaluated, and 5-year overall survival was followed up. The classified data were described by percentages, and the continuous data were described by standard deviations or medians. Univariate analysis was performed using the χ 2 test or rank-sum test, followed by Kaplan-Meier survival analysis to calculate the median survival time and 5-year cumulative survival. A multivariate Cox regression model was used to evaluate the independent risk factors affecting survival. The test level was α = 0.05. Results: Patients were followed up for 0 to 60 months, the 5-year overall survival rate was 36.2%, and the median survival time was 53.0 ± 1.461 months. K-M and log-rank test results revealed that tumor location, degree of differentiation, depth of invasion, regional lymph node involvement, and postoperative tumor stage were correlated with a decreased 5-year survival rate (P < 0.05). A multivariate Cox risk regression model was used to analyze the degree of histological differentiation (HR = 1.441; 95% CI = 1.049-1.979; P = 0.024), regional lymph node (HR = 1.626; 95% CI = 1.160-2.279; P = 0.005), and pTNM stage (HR = 2.266; 95% CI = 1.335-3.847; P = 0.002), which are independent risk factors for poor survival. Tumor location (P = 0.191), invasion depth (P = 0.579) and tumor size (P = 0.324) were not found to be independent risk factors. Conclusion: The degree of tumor differentiation, regional lymph node metastasis and postoperative pathological stage were found to be independent risk factors for 5-year overall survival in patients with advanced gastric cancer. Standardized and reasonable lymph node dissection and accurate postoperative pathological staging were very important.

show abstract

Section: Discussionmentioning

confidence: 99%

Analysis of multiple factors influencing the survival of patients with advanced gastric cancer

Zhu,

Ge,

Wen

et al. 2024

Aging

View full text Add to dashboard Cite

show abstract

“…The results of our study have suggested a tendency towards higher three-year disease-free survival rate with perioperative SOX for patients with resectable stage II/III gastric cancer compared to the adjuvant SOX. The results of the subgroup analysis provide compelling evidence supporting the recommendation in the Chinese guidelines for administering neoadjuvant chemotherapy in stage III patients [ 11 ]. The limitations of this study include potential deviations in stage or response evaluation, the absence of using Lauren’s classification and microsatellite instability status, and the uneven number of enrolled cases across different centers.…”

mentioning

confidence: 86%

Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trial

Wang,

Lu,

Wei

et al. 2024

J Hematol Oncol

Self Cite

View full text Add to dashboard Cite

Evidence from Europe shows that perioperative chemotherapy may be beneficial for the treatment of locally advanced gastric cancer, but reliable and robust data is lacking. To rectify this, the phase 3 RESONANCE trial investigated the efficacy and safety of S-1 plus oxaliplatin (SOX) as a perioperative chemotherapy regimen for gastric cancer. This randomized, open-label trial enrolled patients from 19 medical centers with stage II/III resectable gastric cancer who were centrally randomly assigned to either perioperative chemotherapy (PC) arm or adjuvant chemotherapy (AC) arm. Patients in the PC arm received two to four cycles of SOX followed by surgery and four to six cycles of SOX. Patients in the AC arm received upfront surgery and eight cycles of SOX. 386 patients in each group were enrolled and 756 (382 in PC and 374 in AC) were included in the mITT population. The three-year DFS rate was 61.7% in the PC arm and 53.8% in the AC arm (log-rank p = 0.019). The R0 resection rate in the PC arm was significantly higher than that in the AC arm (94.9% vs. 83.7%, p < 0.0001). There was no difference between two arms in surgical outcomes or postoperative complications. Safety-related data were like the known safety profile. In conclusion, from a clinical perspective, this trial indicated a trend towards higher three-year disease-free survival rate with perioperative SOX in stage II/III resectable gastric cancer with well-tolerated toxicity compared to adjuvant SOX, which might provide a theoretical basis for applying perioperative SOX in advanced gastric cancer patients. (ClinicalTrials.gov NCT01583361)

show abstract

“…These clinical trials successfully revealed that ICIs produce favourable GC therapeutic effects [ 57 ].…”

Section: Clinical Trials That Have Evaluated Immune Checkpoint Inhibi...mentioning

confidence: 99%

Immunotherapy Based on Immune Checkpoint Molecules and Immune Checkpoint Inhibitors in Gastric Cancer–Narrative Review

Poniewierska-Baran,

Sobolak,

Niedźwiedzka-Rystwej

et al. 2024

IJMS

View full text Add to dashboard Cite

Due to its rapid progression to advanced stages and highly metastatic properties, gastric cancer (GC) is one of the most aggressive malignancies and the fourth leading cause of cancer-related deaths worldwide. The metastatic process includes local invasion, metastasis initiation, migration with colonisation at distant sites, and evasion of the immune response. Tumour growth involves the activation of inhibitory signals associated with the immune response, also known as immune checkpoints, including PD-1/PD-L1 (programmed death 1/programmed death ligand 1), CTLA-4 (cytotoxic T cell antigen 4), TIGIT (T cell immunoreceptor with Ig and ITIM domains), and others. Immune checkpoint molecules (ICPMs) are proteins that modulate the innate and adaptive immune responses. While their expression is prominent on immune cells, mainly antigen-presenting cells (APC) and other types of cells, they are also expressed on tumour cells. The engagement of the receptor by the ligand is crucial for inhibiting or stimulating the immune cell, which is an extremely important aspect of cancer immunotherapy. This narrative review explores immunotherapy, focusing on ICPMs and immune checkpoint inhibitors in GC. We also summarise the current clinical trials that are evaluating ICPMs as a target for GC treatment.

show abstract

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023

Cited by 20 publications

References 363 publications

Analysis of multiple factors influencing the survival of patients with advanced gastric cancer

Analysis of multiple factors influencing the survival of patients with advanced gastric cancer

Perioperative versus adjuvant S-1 plus oxaliplatin chemotherapy for stage II/III resectable gastric cancer (RESONANCE): a randomized, open-label, phase 3 trial

Immunotherapy Based on Immune Checkpoint Molecules and Immune Checkpoint Inhibitors in Gastric Cancer–Narrative Review

Contact Info

Product

Resources

About